e-Bio is a clinical-stage medical device company developing an electrically stimulating device designed to diminish or stop uterine contractions in preterm pregnancies. Its proprietary electric-inhibition technology has progressed from animal studies to FDA-authorized human clinical trials, with the first phase supported by a March of Dimes grant. The company is led by CEO Denis Schapira Wajman, Chief Medical Officer Frederick Naftolin, and Chief Scientific Officer Jeffrey Karsdon.
FDA Investigational Device Exemption (IDE)
compliance_program